Vaccibody is seeking partners for its first Product candidate, VB10.16, a DNA vaccine delivered by a needle-free jet injector currently tested in a clinical phase I/IIa study to treat HPV16 induced precancerous cervical lesions. See: https://www.clinicaltrials.gov/ct2/show/NCT02529930 for more information.
The platform proof of concept has been extensively confirmed by academic and industrial partners and novel product candidates under developement are open for early stage partnering discussions.
Vaccibody has entered an industrial licensing agreement with a veterinary vaccine company for the utilization of the Vaccibody technology in development of poultry vaccines.
For enquiries and further information please contact:
CEO, Martin Bonde
JP Morgan, San Francisco, 9-11 Jan
Next Gen Immuno-Oncology, London, 14-15 March
Bio Europe Spring, Barcelona, 20-22 March
NeoAntigen Summit EU, Amsterdam, 24-26 April
Personalized Immunotherapy, Philaldelphia, 2-4 May
Bio International Convention, San Diego, 19-22 June